Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 7/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.45 |
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112360 | 0.77 | CCNE2 (0.46) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL10517093 | 0.75 | CCNE2 (0.44) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL17514112 | 0.75 | CCNE2 (0.51) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL22349056 | 0.75 | ALDH1A1 (0.42) | CCNE2CCNE1CDK2PDE4BALDH1A1 | |
| SCHEMBL11786604 | 0.75 | CCNE2 (0.48) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| Hydrochloric Acid SCHEMBL7007880 | 0.74 | CCNE2 (0.44) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL11395584 | 0.73 | CDK2 (0.43) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| Acetic Acid SCHEMBL11790811 | 0.73 | CCNE2 (0.47) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL5173971 | 0.71 | PDE4B (0.55) | CCNE2CCNE1CDK2CCNB2CDK1 | |
| SCHEMBL1973503 | 0.71 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | PDE4B, PDE4A, PDE3B | CCNE2 4401/4885CCNE1 4092/4885CDK2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.